Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel Free WINT Stock Alerts

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.0003 +0.00 (+50.00%)
As of 09/3/2026 11:20 AM Eastern
Compare

WINT vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Windtree Therapeutics stock or one of its competitors? Windtree Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Windtree Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Windtree Therapeutics (NASDAQ:WINT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Alvotech has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Alvotech's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Alvotech had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Windtree Therapeutics. Alvotech's average media sentiment score of 0.92 beat Windtree Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Positive
Windtree Therapeutics Neutral

Summary

Alvotech beats Windtree Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Windtree Therapeutics compare to Apollomics?

Windtree Therapeutics (NASDAQ:WINT) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Apollomics has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Apollomics$8.50MN/AN/AN/AN/A

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Apollomics Neutral

29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Apollomics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Apollomics N/A N/A N/A

Summary

Apollomics beats Windtree Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Windtree Therapeutics compare to Aravive?

Windtree Therapeutics (NASDAQ:WINT) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Aravive is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
AraviveN/AN/AN/A-$0.90N/A

Aravive's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Aravive N/A N/A N/A

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Aravive Neutral

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aravive beats Windtree Therapeutics on 5 of the 6 factors compared between the two stocks.

How does Windtree Therapeutics compare to bioAffinity Technologies?

Windtree Therapeutics (NASDAQ:WINT) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

bioAffinity Technologies' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
bioAffinity Technologies N/A N/A N/A

In the previous week, bioAffinity Technologies had 2 more articles in the media than Windtree Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.66 indicating that Windtree Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Windtree Therapeutics Neutral
bioAffinity Technologies Negative

bioAffinity Technologies has higher revenue and earnings than Windtree Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Summary

bioAffinity Technologies beats Windtree Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Windtree Therapeutics compare to BioVie?

Windtree Therapeutics (NASDAQ:WINT) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, BioVie had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled BioVie'saverage media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
BioVie Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
BioVieN/AN/AN/AN/AN/A

BioVie's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
BioVie N/A N/A N/A

29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioVie beats Windtree Therapeutics on 3 of the 5 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

Export
MetricWindtree TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13K$4.03B$7.26B$12.73B
Dividend YieldN/A3.60%2.53%8.86%
P/E Ratio0.0012.66273.2925.25
Price / SalesN/A1,335.53621.7997.64
Price / CashN/A106.8777.8252.26
Price / Book0.0016.8113.086.14
Net Income-$1.79M-$22.72M$3.47B$349.01M
7 Day PerformanceN/A0.14%0.52%-0.31%
1 Month PerformanceN/A8.27%5.63%0.64%
1 Year PerformanceN/A52.60%25.31%14.83%

Windtree Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
N/A$0.00
+50.0%		N/A-99.6%$13KN/AN/A30
ALVOW
Alvotech
N/A$0.38
flat		N/A-73.0%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-0.7%		N/A+42.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.16
+113.0%		N/A+1,001.7%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WINT) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel